US equities
|
MU
$1,074.61
▲+2.78%
NVDA
$237.01
▼-0.93%
SNDK
$1,715.00
▲+3.28%
AMD
$644.61
▼-0.74%
INTC
$113.76
▲+1.12%
SPCX
$168.98
▼-1.71%
TSLA
$375.37
▼-1.39%
AAPL
$335.62
▲+0.60%
MU
$1,074.61
▲+2.78%
NVDA
$237.01
▼-0.93%
SNDK
$1,715.00
▲+3.28%
AMD
$644.61
▼-0.74%
INTC
$113.76
▲+1.12%
SPCX
$168.98
▼-1.71%
TSLA
$375.37
▼-1.39%
AAPL
$335.62
▲+0.60%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Biocorrx Inc
(OP:
BICX
)
0.2010
UNCHANGED
Delayed Quote
Updated: 11:20 AM EDT, Oct 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biocorrx Inc
< Previous
1
2
3
Next >
BioCorRx Inc. Appoints Former Acting White House Drug Policy Director Richard J. Baum to Strategic Advisory Board
September 10, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
BioCorRx Announces National Drug Codes (NDCs) for LUCEMYRA (lofexidine) Brand and Authorized Generic (AG) SKUs to Ensure Uninterrupted Market Supply
August 25, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Economy
BioCorRx, Inc. Announces Issuance of U.S. Patent Supporting Its Biodegradable Naltrexone Implant Technology
March 11, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Intellectual Property
BioCorRx, Inc. Announces Issuance of U.S. Patent Supporting Its Biodegradable Naltrexone Implant Technology
March 11, 2026
Issued Patent Supports BioCorRx’s Growing Portfolio of Implant-based Naltrexone Technologies
Via
TheNewswire.com
Topics
Intellectual Property
BioCorRx, Inc. Announces Initiation of Clinical Study by Majority-Owned Subsidiary BioCorRx Pharmaceuticals, Inc. Evaluating Long-Acting Naltrexone Implant With or Without Bupropion
January 14, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
BioCorRx Announces Appointment of Louis Lucido as Board Chair
January 06, 2026
Via
TheNewswire.com
BioCorRx Provides Update on OTC Markets Quotation Status and Planned Form S1 Filing
December 24, 2025
Via
TheNewswire.com
Topics
Regulatory Compliance
BioCorRx Announces Appointment of Louis Lucido as Board Chair
January 06, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
BioCorRx Provides Update on OTC Markets Quotation Status and Planned Form S1 Filing
December 24, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Regulatory Compliance
BioCorRx Inc. to Present at the Life Sciences Virtual Investor Forum December 11th
December 10, 2025
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com
From
Virtual Investor Conferences; BioCorRx Inc.
Via
GlobeNewswire
Life Sciences Virtual Investor Forum Agenda Announced for December 11th
December 09, 2025
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
BioCorRx, Inc. Announces Q3 2025 Results: Second Straight Quarter of Meaningful Revenue Driven by LUCEMYRA(R) Acquisition
November 18, 2025
Via
TheNewswire.com
BioCorRx, Inc. Announces Q3 2025 Results: Second Straight Quarter of Meaningful Revenue Driven by LUCEMYRA(R) Acquisition
November 18, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
BioCorRx Reports 3,985% Revenue Growth to $313K in the First Half of 2025 Driven by LUCEMYRA(R) (lofexidine) Sales
August 14, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Death
BioCorRx Reports 3,985% Revenue Growth to $313K in the First Half of 2025 Driven by LUCEMYRA(R) (lofexidine) Sales
August 14, 2025
Via
TheNewswire.com
Topics
Death
BioCorRx Reports Business Update for the First Quarter of 2025
May 20, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Death
BioCorRx Reports Business Update for the First Quarter of 2025
May 20, 2025
Via
TheNewswire.com
Topics
Death
BioCorRx Pharmaceuticals Inc. Announces That it has Acquired LUCEMYRA(R) (lofexidine), an FDA-Approved Opioid Withdrawal Medication, From USWM, LLC
March 10, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
BioCorRx Pharmaceuticals Inc. Announces That it has Acquired LUCEMYRA(R) (lofexidine), an FDA-Approved Opioid Withdrawal Medication, From USWM, LLC
March 10, 2025
ANAHEIM, CA and LOUISVILLE, KY - March 10, 2025 (NEWMEDIAWIRE) - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related...
Via
TheNewswire.com
BioCorRx Reports Business Update for the Second Quarter of 2024
August 15, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Intellectual Property
BioCorRx Reports Business Update for the First Quarter of 2024
May 16, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Death
Intellectual Property
BioCorRx Reports Business Update for the First Quarter of 2024
May 16, 2024
ANAHEIM, CA - (NewMediaWire) - May 16, 2024 - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today...
Via
TheNewswire.com
Topics
Death
Intellectual Property
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
April 03, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Intellectual Property
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
April 03, 2024
ANAHEIM, CA - (NewMediaWire) - April 03, 2024 - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer of innovative treatment programs for substance use and related disorders, today announced that...
Via
TheNewswire.com
Topics
Intellectual Property
BioCorRx Reports Business Update for 2023
April 02, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Death
BioCorRx Reports Business Update for 2023
April 02, 2024
ANAHEIM, CA - (NewMediaWire) - April 02, 2024 - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today...
Via
TheNewswire.com
Topics
Death
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
February 28, 2024
ANAHEIM, CA - (NewMediaWire) - February 28, 2024 - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders,...
Via
NewMediaWire
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
February 28, 2024
ANAHEIM, CA - (NewMediaWire) - February 28, 2024 - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders,...
Via
TheNewswire.com
Topics
Death
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
February 08, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
February 08, 2024
ANAHEIM, CA - (NewMediaWire) - February 8, 2024 - BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders,...
Via
TheNewswire.com
< Previous
1
2
3
Next >
